---
title: "HPV oncogenes shift DNA crosslink repair toward a PRIMPOL-dependent vulnerability"
id: "biorxiv-6-hpv-oncogenes-rewire-dna-crosslink-repair-to-create-a-primpol-dependent"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-6-hpv-oncogenes-rewire-dna-crosslink-repair-to-create-a-primpol-dependent"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.11.10.765685v1?rss=1"
published_at: "2026-11-12T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# HPV oncogenes shift DNA crosslink repair toward a PRIMPOL-dependent vulnerability
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-6-hpv-oncogenes-rewire-dna-crosslink-repair-to-create-a-primpol-dependent
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.11.10.765685v1?rss=1)
- **Published At:** 2026-11-12T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Genome-wide CRISPR screens compared genetic requirements for surviving cisplatin-based chemoradiation in HPV-negative and HPV-positive HNSCC cells, revealing distinct dependencies. - HPV-positive cells tolerate cisplatin-induced interstrand crosslinks without reliance on the **Fanconi anemia** pathway; investigators reported this phenotype also appears after expressing HPV16 E6 and E7 in HPV-negative cells. - The cohort showed increased dependence on **PRIMPOL**-mediated repriming and on post-replicative gap filling by translesion synthesis polymerases for survival under crosslink-induced replication stress. - Data indicated normal recruitment of **BRCA1** to double-strand breaks, but markedly reduced BRCA1 accumulation at cisplatin-stalled replication forks, implying substrate-specific uncoupling of BRCA1 function. - The study team observed that this altered tolerance mechanism creates dependence on dynamic **RAD51** turnover at single-stranded DNA gaps; manipulation of RAD51 dynamics had selective lethality. - Depletion of the RAD51 unloading factor FIRRM, or chemical stabilization of RAD51 filaments, selectively killed HPV-positive and HPV oncogene-expressing cells treated with cisplatin; PRIMPOL depletion rescued that lethality. - Authors noted the findings identify RAD51 filament dynamics as a potential therapeutic vulnerability in HPV-positive HNSCC; the article is a preprint and has not undergone peer review.
## Clinical Analysis & Structured Key Points
[](https://www.biorxiv.org/cdn-cgi/content?id=UgqGsXNlz59BXf0Jdzji_16Xo4KaIlBamZOiL4PHhbY-1794535992.4084113-1.2.1.1-PmroHwjAlyruUyEGNDyrVLlumrIRwJMZLt2VBQpCj8KDgXRrzEvXpS0WDSJajZTW) [Skip to main content](https://www.biorxiv.org/content/10.64898/2026.11.10.765685v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.11.10.765685v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # HPV Oncogenes rewire DNA crosslink repair to create a PRIMPOL-dependent therapeutic vulnerability Julien Dessapt, Marie-Anne Berube, Ottilie Le Doeuff, Nicolas Soucy, Line Balistaire, Beatrice Morin, sadaf Valeh Sheida, Andreanne Blondeau, Yan Coulombe, Elise G. Lavoie, Jean-Yves M.I. Masson, [ View ORCID Profile](http://orcid.org/0000-0002-8504-3370)Samer M.I. Hussein, [ View ORCID Profile](http://orcid.org/0000-0002-5431-8650)Amelie Fradet-Turcotte doi: https://doi.org/10.64898/2026.11.10.765685 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Julien Dessapt 1 CHU de Quebec-Universite Laval Research Center; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Julien%2BDessapt%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Dessapt%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AJulien%2BDessapt%2B) Marie-Anne Berube 1 CHU de Quebec-Universite Laval Research Center; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Marie-Anne%2BBerube%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Berube%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AMarie-Anne%2BBerube%2B) Ottilie Le Doeuff 1 CHU de Quebec-Universite Laval Research Center; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ottilie%2BLe%2BDoeuff%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Le%20Doeuff%20O&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AOttilie%2BLe%2BDoeuff%2B) Nicolas Soucy 1 CHU de Quebec-Universite Laval Research Center; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nicolas%2BSoucy%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Soucy%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ANicolas%2BSoucy%2B) Line Balistaire 1 CHU de Quebec-Universite Laval Research Center; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Line%2BBalistaire%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Balistaire%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ALine%2BBalistaire%2B) Beatrice Morin 1 CHU de Quebec-Universite Laval Research Center; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Beatrice%2BMorin%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Morin%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ABeatrice%2BMorin%2B) sadaf Valeh Sheida 1 CHU de Quebec-Universite Laval Research Center; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=sadaf%2BValeh%2BSheida%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Valeh%20Sheida%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3Asadaf%2BValeh%2BSheida%2B) Andreanne Blondeau 1 CHU de Quebec-Universite Laval Research Center; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Andreanne%2BBlondeau%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Blondeau%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AAndreanne%2BBlondeau%2B) Yan Coulombe 1 CHU de Quebec-Universite Laval Research Center; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yan%2BCoulombe%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Coulombe%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AYan%2BCoulombe%2B) Elise G. Lavoie 1 CHU de Quebec-Universite Laval Research Center; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Elise%2BG.%2BLavoie%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=G.%20Lavoie%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AElise%2BG.%2BLavoie%2B) Jean-Yves M.I. Masson 1 CHU de Quebec-Universite Laval Research Center; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jean-Yves%2BM.I.%2BMasson%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Masson%20JM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AJean-Yves%2BM.I.%2BMasson%2B) Samer M.I. Hussein 1 CHU de Quebec-Universite Laval Research Center; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Samer%2BM.I.%2BHussein%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Hussein%20SM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ASamer%2BM.I.%2BHussein%2B) * [ORCID record for Samer M.I. Hussein](http://orcid.org/0000-0002-8504-3370 "Open in new tab") Amelie Fradet-Turcotte 2 CHU de Quebec - Universite Laval Research Center * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amelie%2BFradet-Turcotte%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Fradet-Turcotte%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AAmelie%2BFradet-Turcotte%2B) * [ORCID record for Amelie Fradet-Turcotte](http://orcid.org/0000-0002-5431-8650 "Open in new tab") * For correspondence: amelie.fradet-turcotte@crchudequebec.ulaval.ca * [Abstract](https://www.biorxiv.org/content/10.64898/2026.11.10.765685v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5957043/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.11.10.765685v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5957043/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.11.10.765685v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5957043/1) * [Supplementary material](https://www.biorxiv.org/content/10.64898/2026.11.10.765685v1.supplementary-material)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_data/node:5957043/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.11.10.765685v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5957043/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Cisplatin-based chemoradiation is the standard of care for both HPV-negative (HPV−) and HPV-positive (HPV+) head and neck squamous cell carcinoma (HNSCC), even though patients with HPV+ tumors have better treatment responses and a better prognosis. Understanding how HPV status shapes this response could guide alternative strategies that lower long-term toxicity. Using genome-wide CRISPR screens, we show that the genetic requirements for surviving chemoradiation diverge between HPV− and HPV+ HNSCC cells. HPV+ cells tolerate cisplatin-induced interstrand crosslinks independently of the Fanconi anemia pathway, a phenotype recapitulated by expressing HPV16 E6 and E7 in an HPV-negative background. In these cells, DNA damage tolerance depends instead on PRIMPOL-mediated repriming and post-replicative gap filling by translesion synthesis polymerases. Although they recruit BRCA1 normally to double-strand breaks, BRCA1 accumulation at cisplatin-stalled forks is markedly reduced, indicating that BRCA1 function is uncoupled between these two substrates. This tolerance pathway leaves cells dependent on dynamic RAD51 turnover at single-stranded DNA gaps. Depletion of the RAD51 unloading factor FIRRM, or chemical stabilization of RAD51 filaments, selectively kills HPV+ and HPV oncogene-expressing cells treated with cisplatin, and PRIMPOL depletion rescues this lethality. Our findings show that HPV oncogenes rewire the response to crosslink-induced replication stress and identify RAD51 filament dynamics as a therapeutic vulnerability in HPV+ HNSCC. ### Competing Interest Statement The authors have declared no competing interest. Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.11.10.765685v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.64898/2026.11.10.760688v1 "A novel interaction between MNT and CCDC6: structural insights and distinct roles in cell migration and the DNA damage response") Posted November 12, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.11.10.765685v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/11/12/2026.11.10.765685.full.pdf)Full Text & In-line FiguresXM
## Related Clinical Research

- [Nelfinavir enhances cisplatin-induced immunogenic cell death in ovarian cancer cells](https://medichelpline.com/clinical-feed/biorxiv-6-combined-nelfinavir-and-cisplatin-treatment-promotes-inflammatory-signaling-and.md)
- [SRSF1 controls transcription and alternative splicing to alter p53 signaling and genome maintenance](https://medichelpline.com/clinical-feed/biorxiv-4-srsf1-coordinates-transcription-and-alternative-splicing-to-modulate-p53-and.md)
- [Correction: Image replacement and data notes for niosomal cisplatin–vorinostat formulation](https://medichelpline.com/clinical-feed/plos-one-19-correction-development-of-niosomal-nanoparticles-loaded-with-cisplatin-and.md)
- [Cobalt‑group metal complexes as anticancer agents: how ligands shape activity](https://medichelpline.com/clinical-feed/pubmed-42929697.md) (DOI: 10.1039/d6dt00899b)
- [Sex Differences in ICI Survival for Advanced NSCLC: Meta-analysis Findings](https://medichelpline.com/clinical-feed/plos-one-15-sex-difference-in-survival-benefits-of-immune-checkpoint-inhibitors-in-advanced.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.